Goldstein Advisors LLC Trims Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Goldstein Advisors LLC reduced its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,731 shares of the medical research company’s stock after selling 726 shares during the quarter. Goldstein Advisors LLC’s holdings in Exact Sciences were worth $322,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in EXAS. Huntington National Bank boosted its stake in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after buying an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC purchased a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $34,000. Capital Performance Advisors LLP purchased a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $35,000. Modus Advisors LLC purchased a new position in shares of Exact Sciences during the 4th quarter valued at approximately $43,000. Finally, Vestor Capital LLC purchased a new position in shares of Exact Sciences during the 3rd quarter valued at approximately $46,000. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Exact Sciences

In related news, CEO Kevin T. Conroy purchased 19,500 shares of Exact Sciences stock in a transaction that occurred on Wednesday, November 13th. The stock was purchased at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.36% of the stock is owned by insiders.

Exact Sciences Stock Up 1.0 %

EXAS stock opened at $54.79 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The stock has a market capitalization of $10.14 billion, a P/E ratio of -46.83 and a beta of 1.24. The business has a 50-day moving average of $57.32 and a 200-day moving average of $59.35. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Exact Sciences Co. will post -1.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EXAS shares. Bank of America reduced their price objective on Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Jefferies Financial Group raised their price objective on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. BTIG Research raised their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a research note on Monday, January 13th. Finally, Piper Sandler reduced their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.